CDKN2B
Cyclin-dependent kinase 4 inhibitor B
Protein Summary
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008]
- ENST00000276925
- ENSP00000276925
- ENSG00000147883
- ENST00000380142
- ENSP00000369487
- MTS2
- P15
- MTS2
- TP15
- CDK4I
- INK4B
- p15INK4b
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0.97 | ||
biological term | 0.95 | ||
PubMedID | 0.9 | ||
gene perturbation | 0.87 | ||
disease | 0.83 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 705.36 (req: < 5)
Gene RIFs: 244 (req: <= 3)
Antibodies: 566 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 705.36 (req: >= 5)
Gene RIFs: 244 (req: > 3)
Antibodies: 566 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 17
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0